CEACAM5 and neoplasm: A phase I clinical trial showed that exosomes extracted from heat-treated carcinoembryonic antigen (CEA) + tumor-derived LS-174 T cells were enriched in CEA, HSP70 and MHC I. Then, the exosomes were co-cultured with mononuclear cells that were extracted from the serum of CEA+ patients, and the resulting sensitized DCs were injected into patients to induce a strong CEA-specific T cell anti-tumor effect.